A
Angel R. Garcia
Researcher at Harvard University
Publications - 9
Citations - 1727
Angel R. Garcia is an academic researcher from Harvard University. The author has contributed to research in topics: Personality & EGFR inhibitors. The author has an hindex of 8, co-authored 9 publications receiving 1491 citations.
Papers
More filters
Journal ArticleDOI
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst,Lecia V. Sequist,John T. Poirier,Craig H. Mermel,Elizabeth L. Lockerman,Angel R. Garcia,Ryohei Katayama,Carlotta Costa,Kenneth N. Ross,Teresa Moran,Emily Howe,Linnea Fulton,Hillary E. Mulvey,Lindsay A. Bernardo,Farhiya Mohamoud,Norikatsu Miyoshi,Paul A. VanderLaan,Daniel B. Costa,Pasi A. Jänne,Darrell R. Borger,Sridhar Ramaswamy,Toshi Shioda,Anthony J. Iafrate,Gad Getz,Charles M. Rudin,Mari Mino-Kenudson,Jeffrey A. Engelman +26 more
TL;DR: Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC.
Journal ArticleDOI
The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies
Matthew J. Niederst,Haichuan Hu,Hillary E. Mulvey,Elizabeth L. Lockerman,Angel R. Garcia,Zofia Piotrowska,Lecia V. Sequist,Jeffrey A. Engelman +7 more
TL;DR: The results demonstrate that the allelic context in which C797S was acquired may predict responsiveness to alternative treatments, and are a novel mechanism of acquired resistance to third-generation TKIs.
Journal ArticleDOI
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor
Zofia Piotrowska,Matthew J. Niederst,Chris Karlovich,Heather A. Wakelee,Joel W. Neal,Mari Mino-Kenudson,Linnea Fulton,Aaron N. Hata,Elizabeth L. Lockerman,Anuj Kalsy,Subba R. Digumarthy,Alona Muzikansky,Mitch Raponi,Angel R. Garcia,Hillary E. Mulvey,Melissa Parks,Richard H. DiCecca,Dora Dias-Santagata,A. John Iafrate,Alice T. Shaw,Andrew R. Allen,Jeffrey A. Engelman,Lecia V. Sequist +22 more
TL;DR: It is documents that half of T790M-positive EGFR-mutant lung cancers treated with rociletinib are T790-wild-type upon progression, suggesting that T790, wild-type clones can emerge as the dominant source of resistance.
Journal ArticleDOI
Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome) : a preliminary report
TL;DR: A knockout mouse model of MPS II which has been used to assess the effect of enzyme replacement therapy and to support the first clinical trial of recombinant IDS in patients with Hunter syndrome is described.
Journal ArticleDOI
Factors associated with outcome in major depression: a 6-month prospective study
TL;DR: The presence of personality disorders, having suffered a previous episode, GAF score and some aspects of social support were the variables most associated with non full remission in the logistic regression analysis and personality disorders and the initial HAM-D score were related to non-improvement.